Founded in 2016, BICO (formerly CELLINK) is the world’s leading bioconvergence company, organized into three business areas: Biosciences, Bioautomation, and Bioprinting.
Our products aim to reduce the organ shortage and speed up drug development by providing accessible life science solutions that combine biology and technology, fundamentally shifting the global healthcare industry. Read more at BICO.com
Using a combination of robotics, artificial intelligence, advanced genomics, and 3D bioprinting, our innovative technologies enable researchers and practitioners in the life sciences to conduct cell line development, perform high-throughput drug screening and diagnostics, and print human tissues and organs for the medical, pharmaceutical, and cosmetic industries. BICO is the future of life-saving treatments, as we enable our customers to improve people’s health and lives.
We have over 32,000 installed instruments in more than 3,500 laboratories, including the top 20 pharmaceutical companies. They are being used in more than 65 countries, and have been cited in more than 11,000 publications. BICO is listed on Nasdaq Stockholm under BICO.
CYTENA Bioprocess Solutions Co., Ltd (CBS) is founded in 2018 as a subsidiary of BICO (formerly CELLINK) , a world leading bioconvergence group. CYTENA Bioprocess Solutions focuses on offering bioprocess solutions for, but not limited to pharmaceuticals and top research institutes.
We have established collaboration with leading academic institutes and industrial companies in researching, development, and application. With the close connection with BICO, we share the resources, experiences to bring our novel and comprehensive product into the global bioprocess market.
We have great worldwide network with top pharmaceuticals and research institutes. That makes our developing product will be adhered to your requirement.
Our great international team spirit brings us to a good start. With our young and creative members, we will bring whole team to the next impressive stage.
More than three public funding have been granted from both Taiwan and German government from 2019 to 2021. We will engage in utilize these funding and turn out with maximum output.
As a spin-off company from cytena GmbH, Germany, we share all the connections and resources worldwide. Our global networks drive us get deep into the field and expand the market rapidly.
Quality, utility and usability are the key factors in the success of a product. Quality means for us to always tackle things right and meaningful.
Therefore we build reliable and robust products. The customers need to get maximum benefit from our products.
By entering your email, you agree to our Terms of Service and Privacy Statement
CYTENA BPS is a part of BICO. Our products aim to reduce the organ shortage and speed up drug development by providing accessible life science solutions that combine biology and technology, fundamentally shifting the global healthcare industry.
